International Journal of Drug Delivery Technology
Volume 15, Issue 2

Medicinal Plants as Powerful and Efficient Sources of Diabetes Treatment Compared to Medicinal Insulins : Case Study Dukagjin Region in Kosovo

Arber Dreshaj1, Donika Veseli1, Altin Dreshaj2*, Florim Bajraktari3

1Department of Pharmacy, Faculty of Medicine, University of Pristina. Kosovo

2Department of Dentistry, Faculty of Medicine, University of Pristina. Kosovo

3General Hospital Peja, Orthopedic department, St. Mother Teresa, Peja-30000, Kosovo

Received: 14th Dec, 2024; Revised: 23rd Mar, 2025; Accepted: 3rd May, 2025; Available Online: 25th Jun, 2025

ABSTRACT

The use of medicinal plants is a promising resource for the treatment of diabetes in Kosovo. In traditional medicine, a healthy lifestyle is the best way to prevent diabetes. The research of the study is the treatment of diabetes mellitus type 1 and 2, the role of insulin therapy and an overview of the use of medicinal plants used in the treatment of diabetes.The method is based on the collection of data on the number of patients with DM type 1 and 2, obtained from the protocols of the Regional Hospital of Peja and Family Medicine Centers in the municipality of Dukagjin. Also, data on the treatment of patients with insulin were obtained from scientific research in medical journals published in academic databases such as: (Scopus Web of Science, Elsevier., etc.). Number of samples in the study 154 patients.Statistics show that the treatment of patients with insulin such as Linagliptin and Steglujan results in the adequate treatment of (87.5%) of patients. The lowest insulin failure rate of Glyxambi, Soliqua, Ertugliflozin and Xultofia is up to (70%) in some patients. Treatment of patients with phytotherapeutic medicinal plants such as: Rosa Canina, Viccinium Berrica, Urtica etc., the results show a better and higher treatment effect, ranging from (85.71% - to 91.43%). The use of medicinal plants for antidiabetic treatment has an advantage of (4.81%) compared to insulin treatment.The results of the study are really promising in finding the solution for the prevention of diabetes, especially the orientation of patients with DM, in the use of antidiabetic herbs.

Keywords: Diabetes, metabolism, glucose, insulin, medicinal plants.

How to cite this article: Arber Dreshaj, Donika Veseli, Altin Dreshaj, Florim Bajraktari. Medicinal Plants as Powerful and Efficient Sources of Diabetes Treatment Compared to Medicinal Insulins : Case Study Dukagjin Region in Kosovo. International Journal of Drug Delivery Technology. 2025;15(2):406-15. doi: 10.25258/ijddt.15.2.5

REFERENCES

  1. Amin SS, Jogdand SD. Prescribing Pattern of Antidiabetic Drugs and Its Adherence to American Diabetes Association Guidelines in Patients of Type 2 Diabetes Mellitus with and Without Comorbidities. International Journal of Drug Delivery Technology. 2024;14(3):1908-1913.
  2. Nagansurkar SB, Yadav HKS, Abhay R. Formulation and Evaluation of Electrospun Nanofiber Mats of Curcumin and Leaf Extract of Tinospora cordifolia: Designed for Accelerating Diabetic Wound Healing. International Journal of Drug Delivery Technology. 2024;14(2):687-692.
  3. Pise AG, Ghuse H, Zade S, Tiwaskar GH. Development and Assessment of a Nutritional Supplement Formulation for Diabetes Mellitus. International Journal of Drug Delivery Technology. 2024;14(2):759-767.
  4. Shraddha RS, Kumar B, Neeraj SK, Manmohan S, Swati A. In-vitro Analysis of Antioxidant, AntiInflammatory, Antidiabetic and Antimicrobial Studies of Kaempferol Ethosomes. International Journal of Drug Delivery Technology. 2024;14(1):118-125.
  5. Singh M, Rao DBS, Soni V, Minhas PS, Amudha S. Development and Evaluation of Polyherbal Gel for Treatment of Diabetic Neuropathy. International Journal of Drug Delivery Technology. 2024;14(1):165-168.
  6. Mani S, Veeraputhiran A. Design and Assessment of Boswellia Nanofibers for Diabetes Wound Healing. International Journal of Drug Delivery Technology. 2024;14(1):169-173.
  7. Lote S, Kshirsagar M, Mohale D, Chandewar A. Comprehensive Study of Ehretia laevis in Treatment of Diabetes and Related Complications. International Journal of Drug Delivery Technology. 2024;14(1):412-416.
  8. Farman HA, Naji RR. Evaluation of Growth-differentiation Factor-15 Level and few Physiological Parameters Patients with Diabetes Mellitus Type 2. International Journal of Drug Delivery Technology. 2024;14(1):442-446.
  9. Dreshaj, A., Dreshaj, A., Sinanaj, D., Morina, E., &Amp; Dehari, Sh. (2024). Main consequences of enzymatic induction and inhibition during the interaction of drugs and the role of CYP3A4, CYP3A45 enzymes. https://doi.org/10.2478/cipms-2024-0001.
  10. Nemade M, Patil K, Bedse A, Chandra P, Ranjan R, Tare H, Bhise M. Phenol Glucosides as Potential Inhibitors of SGLT1 for Enhanced Diabetes Mellitus Treatment in Patients with Declining Renal Function. International Journal of Drug Delivery Technology. 2023;13(3):948-954.
  11. Bhavani MS, Saravanan R. Beyond Syringes and Pills: Advances in Drug Delivery Systems for. Diabetes. International Journal of Drug Delivery Technology. 2023;13(3):1069-1077.
  12. Mukhopadhyay P, Biswas A, Biswas G. Diabetes Self-Efficacy and Its Relationship with Self-Care and Glycaemic Control Among Elderly Patients with Type 2 Diabetes Mellitus. Natl J Community Med [Internet]. 2023 Dec. 1 [cited 2024 Oct. 30];14(12):793-9. Available from: https://www.njcmindia.com/index.php/file/article/view/3338
  13. Henry Rr., Murray Av., Marmolejo Mh., Hennicken D., Ptaszynska A., List Jf. DAPAGLIFLOZIN, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int J Clin Pract. 2012 May;66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x. Epub 2012 Mar 13. PMID: 22413962.
  14. Ba J., Han P., Yuan G., Mo Z., Pan C., Wu F., Xu L., Hanson Me., Engel Ss., Shankar Rr. A randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017 Jul;9(7):667-676. doi: 10.1111/1753-0407.12456.
  15. Raedler La. Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):171-5. PMID: 26629285; PMCID: PMC4665058.
  16. Askar R., Fredriksson E., Manell E. et al.Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits. BMC Vet Res16, 436 (2020). https://doi.org/10.1186/s12917-020-02618-7.
  17. Del Prato S., Barnett Ah., Huisman H., Neubacher D., Woerle Hj., Dugi Ka. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011 Mar;13(3):258-67. doi: 10.1111/j.1463-1326.2010.01350.x. PMID: 21205122.
  18. Li L., Zhang Q., Yang D., Yang S., Zhao Y., Jiang M., Wang X., Zhao L., Liu Q., Lu Z., Zhou X., Gan Y., Wu C. Tooth loss and the risk of cognitive decline and dementia: A meta-analysis of cohort studies. Front Neurol. 2023 Apr 17;14:1103052. doi: 10.3389/fneur.2023.1103052. PMID: 37139053; PMCID: PMC10150074.
  19. Davies M., Chatterjee S., Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016 Jun 23;8:61-81. doi: 10.2147/CPAA.S82008. PMID: 27382338; PMCID: PMC4922775.
  20. Wittström F., Skajaa N., Bonnesen K., Pedersen L., Ekholm O., Strate L., Erichsen R., Sørensen Ht. Type 2 diabetes and risk of diverticular disease: a Danish cohort study. BMJ Open. 2022 Feb 21;12(2):e059852. doi: 10.1136/bmjopen-2021-059852. PMID: 35190447; PMCID: PMC8862453. Angadi N, Shubha DB. Social Support and Medication Adherence Among People with Type 2 Diabetes Mellitus in Central Karnataka, India. Natl J Community Med [Internet]. 2023 Dec. 1 [cited 2024 Oct. 30];14(12):834-41. Available from: https://www.njcmindia.com/index.php/file/article/view/3301
  21. G K, J I, AN A, IMPS I. The prevalence and related factors of pre‐diabetes and diabetes among overweight and obese children in Urban schools. Natl J Community Med [Internet]. 2022 Jan. 31 [cited 2024 Oct. 30];13(01):27-31. Available from: https://www.njcmindia.com/index.php/file/article/view/54
  22. Mohammad RH, Mohammed MM, Hlail AA. Effect of Adding Taurine to Gabapentin on Toronto Clinical Neuropathy Score in Patient with Diabetic Neuropathy. International Journal of Drug Delivery Technology. 2023;13(3):1117-1124.
  23. Mahan SJ, Mahammad MM. Depression and Associated Factors among Type 2 Diabetics in Karbala City, Iraq: As a Model of Anti-Depressant Drugs. International Journal of Drug Delivery Technology. 2023;13(3):1125-1130.
  24. Kadhim SA, Saleh ES, Jaafar AD. Assessment of Serum Levels of the WNT Pathway Antagonist (Dickkopf-1) in a Sample of Type 2 Diabetic Patients with Retinopathy using Two Groups of Antidiabetics. International Journal of Drug Delivery Technology. 2023;13(2):488-493.
  25. Izzat SE, Saeed GT. Significance of Blink Reflex as a Neurophysiological Marker of Diabetic Peripheral Neuropathy. International Journal of Drug Delivery Technology. 2023;13(2):538-541.
  26. Salman OD, Merdaw MAZ, Almaliky AA. The Probable Association between Type 2 Diabetes Mellitus and Toxoplasma gondii Infection. International Journal of Drug Delivery Technology. 2023;13(1):131-135.
  27. Zaboon MA, Jasim EW, Detection of the Effect of Adiponectin, Vitamin D on Few Biochemical Parameters in Type2 Diabetes Mellitus. International Journal of Drug Delivery Technology. 2022;12(4):1748-1750.
  28. Majeed SH, Mshimesh BAR, Salman IN, Effect of Berberine Supplement in Iraqi Sample of Type 2 Diabetic Patients with Recurrent Urinary Tract Infections. International Journal of Drug Delivery Technology. 2022;12(4):1916-1923.
  29. Gaikwad DT, Bansode1 SP, Mali DP, Wadkar GH, Pawar VT, Tamboli FA. Promising Discovery of Alpha Amylase Enzyme Inhibitors from Terminalia arjuna for Antidiabetic Potential. International Journal of Drug Delivery Technology. 2022;12(3):1020-1024.
  30. Alsaqa SA, Yonis RA. Role of Sural Sensory Nerve in The Assessment of Type 2 Diabetes Mellitus Peripheral Polyneuropathy in Adults. International Journal of Drug Delivery Technology. 2022;12(3):1124-1128.
  31. Dreshaj, A., Dreshaj, A., Veseli, D., Sinanaj, D., Morina, E., &Amp; Dehari, Sh. (202 4). Association between glycosylated hemoglobin and newly diagnosed hypertension in a non-diabetic kosovar population: a cross-sectional analysis. Medicni perspektivi. 2024;29(2):79-87. https://doi.org/10.26641/2307-0404.2024.2.307579.
  32. Hmood AR, Alhibaly HA, Algraittee SJR, Bdair BWH. Restoration of Euglycemia in Type 2 Diabetes Patients with Pioglitazone as Fourth Drug in Oral Combination Therapy: An Experimental Study. International Journal of Drug Delivery Technology. 2022;12(1):46-50.
  33. Mohammed SH, Hussein AL. Evaluation of Serum Ghrelin Level in Patients with Type 2 Diabetes Mellitus Before and After Supplementation of 5000 IU of Vitamin D. International Journal of Drug Delivery Technology. 2022;12(1):66-69.
  34. Attia ZM, Hammood HJ Assi MA. Assessment of Oxidative Stress Biomarker (8-OHdG) and Paraoxonases 1 in Type II Diabetic Mellitus. International Journal of Drug Delivery Technology. 2021;11(4):1389-1393.
  35. Atheeb AK, Hussein SZ, Al-Mudhaffar SS. Oxidative Stress Status in Sera of Type 2 Diabetic Iraqi Patients with Coronary Artery Diseases. International Journal of Drug Delivery Technology. 2021;11(2):291-297.
  36. Oohayeed NA, Naïf HM. Molecular Genotyping of Rotavirus Associated with Type 1 Diabetes Mellitus in Iraqi Children. International Journal of Drug Delivery Technology. 2021;11(2):601-606.
  37. Dreshaj, A., et al. "Effect of the Impurities on Drugs, Metabolism, and the Role of the Isoenzyme CYP3A4" Acta Medica Bulgarica, vol. 51, no. s2, Sciendo, 2024, pp. 47-54. https://doi.org/10.2478/amb-2024-0052.